Search Results

Upcoming Events & Meetings "Evolving Management of Carcinoid Heart Disease: What We Know & What's New" April 29, 2025 Learn from Cardiologist and Congenital Heart Disease Specialist, Dr. Prashanth Venkatesh from Cedars-Sinai Smidt Heart Institute in a virtual educational event on carcinoid heart disease. Dr. Venkatesh demystifies the topic and shares the latest developments in its diagnosis and treatment, including a novel minimally invasive approach to replace heart valves damaged by carcinoid heart disease. Register NCF Regional NET Patient Educational Event May 17, 2025 The Neuroendocrine Cancer Foundation is hosting an in-person Neuroendocrine Cancer Educational Event for patients and caregivers in Santa Monica, California on Saturday, May 17th, from 3:45 -7:30 PM. Register 2025 NCF Neuroendocrine Cancer Patient Conference June 14, 2025 Registration to Open Soon NCF Regional NET Patient Educational Event Nov 8, 2025 Registration to Open Soon Virtual NET Patient & Caregiver Support Group (Weekly) Wednesday, Apr. 16, 23, 30. May 7, 14, 21, 28, 2025 NOON - 1:30 PM Pacific Join NCF via ZOOM Weekly on Wednesdays from 12 - 1:30 PM Pacific Time. We provide a collective, empathetic space for information & experience sharing, support & community. For NET Patients & Caregivers REGISTER Virtual NET Caregiver Support Group (Monthly on a Saturday) Next meeting Apr. 26, 8:00 - 10:00 AM Pacific We provide a safe space where NET caregivers can come together virtually for support and community. We encourage you to express your experiences, thoughts, and concerns amongst fellow caregivers. For NET caregivers only REGISTER Click here for recent events

< Back to the upcoming events page WATCH THE RECORDING Celebrate NET Cancer Day at the LACNETS NET Cancer Day Symposium in Santa Monica, California on Saturday, November 9th from 8:30 am - 3:30 pm. ABOUT Hear presentations from local NET experts and stories from those in the neuroendocrine cancer community. Learn about the latest in surgery, medical treatments, PRRT, symptom management, and clinical trials. Ask questions during the live question and answer sessions. Find out how you can spread awareness about neuroendocrine cancer. Show how you live well with Neuroendocrine Cancer in our "Show & Tell" Video Slideshow (will be played during our reception). Post-Event Ice Cream Social There is no cost to attend. This event is made possible by the generosity of donors and sponsors. This event will not be broadcast. LOCATION Santa Monica Bay Woman's Club 1210 4th St, Santa Monica, CA 90401 Parking will be fully validated at SP+ Parking Garage Structure 1 at 1234 4th St, Santa Monica, CA. AGENDA *Subject to change. Please check back closer to the event for the most accurate agenda. Time Topic Speaker 8:30 - 9 AM Registration & Breakfast 9 - 9:10 AM Welcome LACNETS Team 9:10 - 9:20 AM A NET Impact Story A NET Patient 9:20 - 9:35 AM A NET Surgeon's Perspective on What to Ask Your Surgeon & How to Prepare for Surgery Alexandra Gangi, MD, Surgical Oncologist, Cedars-Sinai 9:35 - 9:50 AM Alpha vs Beta PRRT: Which is for me? Martin Auerbach, MD, Nuclear Medicine, UCLA 9:50 - 10:20 AM Q&A Alexandra Gangi, MD, Surgical Oncologist, Cedars-Sinai & Martin Auerbach, MD, Nuclear Medicine, UCLA 10:20 - 10:50 AM Break 10:50 - 10:55 AM A NET Impact Story A NET Caregiver 10:55 - 11:15 AM The Latest in NET Medical Therapies Andrew Hendifar, MD, Medical Oncologist, Cedars-Sinai 11:15 - 11:35 AM The Endocrine in Neuroendocrine Run Yu, MD, Endocrinologist, UCLA 11:35 - 11:50 AM Liver Directed Therapy for Neuroendocrine Liver Tumors H. Gabriel Lipshutz MD, Interventional Radiologist, Cedars-Sinai 11:50 AM - 12:30 PM Q&A All Faculty (Moderated by Lisa Yen) 12:30 - 1:30 PM Lunch & Networking 1:30 - 2:05 PM The Future of NETs: Evolving Treatments & Clinical Trials Jaydira Del Rivero, MD, Medical Oncologist, Endocrinologist, National Cancer Institute, National Institutes of Health 2:05 - 2:25 PM Spreading Awareness Globally: INCA's Think NENs Stephanie Alband, INCA President & PPA Executive Director 2:25 - 2:35 PM Let's Talk About NETs: How YOU Can Spread Awareness Heather Davis, LACNETS Associate Director of Advocacy & Outreach 2:35 - 3:00 PM Music Heals Drum Healing with John Fitzgerald 3:05 - 3:15 PM Closing LACNETS Team 3:15 - 4:30 PM Networking Reception with Show & Tell Slideshow MODERATORS : Andrew Hendifar, MD, & Lisa Yen, Director of Programs and Outreach SPEAKERS: ALEXANDRA GANGI, MD Surgical Oncologist, Cedars-Sinai Medical Center Dr. Alexandra Gangi is a board-certified surgical oncologist at Cedars-Sinai Medical Center in Los Angeles. Dr. Gangi completed a general surgical residency at Cedars-Sinai and completed her surgical oncology fellowship at the H. Lee Moffitt Cancer Center in Tampa, Florida. She currently serves as the director of the Gastrointestinal Tumor and Cancer Regional Therapies Programs with specialization in Pancreatic and GI Neuroendocrine tumors, Metastatic colorectal cancer, and Peritoneal Surface Malignancies. Her research focuses on understanding GEPNET heterogeneity between and within tumors subtypes and mechanisms of chemotherapy induced liver injury. ANDREW HENDIFAR, MD Medical Oncologist, Cedars-Sinai Medical Center The current research focus of Andrew Hendifar, MD, is on developing new therapies for pancreatic cancer and neuroendocrine tumors. Dr. Hendifar has helped form multidisciplinary teams that specialize in the treatments of pancreatic cancer, and carcinoid and neuroendocrine tumors. Dr. Hendifar is the primary investigator for several groundbreaking therapies, including radioimmunotherapy for neuroendocrine tumors, anti-inflammatory therapy for pancreatic cancer and novel approaches to cancer cachexia. His national roles include SWOG GI Committee Member and a member of NIH Neuroendocrine Tumor Task Force. He also serves as the steering committee member for the Precision Promise Consortium and chairs the associated Supportive Care Committee. At Cedars-Sinai, he leads the Gastrointestinal Disease Research Group and is the founding Director of the Hematology and Oncology Fellowship Program. MARTIN AUERBACH, MD Nuclear Medicine, UCLA Dr. Allen-Auerbach is the Medical Director of UCLA Nuclear Medicine and Clinical Professor in Nuclear Medicine, Division of Pharmacology, at the David Geffen School of Medicine at UCLA. Apart from serving as attending physician in Nuclear Medicine, active research includes clinical studies investigating the role of molecular imaging with PET/CT to gain insights into malignant disease processes and as well as applications of Nuclear Medicine for the treatment of cancer. RUN YU, MD, PhD Endocrinologist, UCLA Run Yu, MD, PhD, received his MD degree from Peking Union Medical College in Beijing and his PhD degree in pharmacology from University of Rochester in New York. Dr. Yu completed an endocrine research fellowship, an internal medicine residency, and a clinical endocrinology fellowship at Cedars-Sinai Medical Center. Dr. Yu’s clinical and research interests include diabetes, thyroid, and endocrine tumors and syndromes. Dr. Yu enjoys describing novel clinical findings in endocrinology. H. GABRIEL LIPSHUTZ, MD Interventional Radiologist Cedars-Sinai Medical Center H. Gabriel Lipshutz, MD is a board-certified, fellowship-trained vascular and interventional radiologist with the Cedars-Sinai S. Mark Taper Foundation Imaging Center. Dr. Lipshutz performs all peripheral endovascular and interventional procedures including embolizations and minimally invasive oncological treatments (chemoembolization, Y-90 radioembolization, RFA, cryoablation, microwave ablation, and irreversible electroporation (IRE). His responsibilities include consultation and treatment of outpatients and inpatients, including the evaluation of patients in the IR outpatient clinic. After earning his bachelor's degree from Wesleyan University, Dr. Lipshutz earned his medical degree from the University of California, San Francisco. He completed his internship in internal medicine at the University of Washington, his radiology residency at the Oregon Health and Sciences University, and his fellowship in interventional radiology at UCLA. JAYDIRA DEL RIVERO, MD Medical Oncologist & Endocrinologist National Cancer Institute, National Institutes of Health Dr. Del Rivero earned her medical degree from the University of Veracruz in Veracruz, Mexico and completed her internal medicine residency at Woodhull Medical and Mental Health Center/NYU-Langone Medical Center. Dr. Del Rivero completed a fellowship in Endocrinology, Diabetes and Metabolism at The Inter-Institute Endocrinology Training Program (IETP) at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), The National Institute of Child Health and Human Development (NICHD), and The National Institute of Dental and Craniofacial Research (NIDCR) where she was part of a research team developing clinical trials for pheochromocytoma and paraganglioma. She then joined as Assistant Professor at the Montefiore Einstein Center for Cancer Care (MECCC) where she specialized in endocrine oncology involving thyroid cancer, parathyroid and adrenal tumors, and clinical research for gastroenteropancreatic neuroendocrine tumors. She subsequently completed a second fellowship in medical oncology at the National Cancer Institute (NCI) with a research focus on endocrine malignancies. Dr. Del Rivero is board certified in Internal Medicine, Endocrinology, Diabetes and Metabolism and Medical Oncology. Dr. Del Rivero is a Physician Scientist in the Developmental Therapeutics Branch. She is the Principal Investigator of the Natural History Study for Neuroendocrine Neoplasm and Adrenocortical Cancer to provide the basis of further development of therapeutic interventions, prevention/screening guidelines, endpoints for future clinical trials, and patient reported outcome measures. Dr. Del Rivero’s current efforts is the development of novel treatment approaches and targeted therapies for endocrine malignancies such as advanced gastroenteropancreatic neuroendocrine tumors, adrenocortical cancer and pheochromocytoma/paraganglioma. STEPHANIE ALBAND, MSBA Board President, INCA Executive Director, The Pheo Para Alliance Stephanie Alband, MSBA, joined Pheo Para Alliance in March of 2019. She has over 20 years of experience in the nonprofit industry, with ten years working exclusively for rare disease organizations, including the Huntington’s Disease Society of America and Angioma Alliance. Her experience with her daughter’s rare cancer has helped her better understand and successfully navigate the unique challenges faced by the rare disease community. She currently serves as the President for the International Neuroendocrine Cancer Alliance (INCA) and previously served as Communications Chair and a Member of the Board of Directors. JOHN FITZGERALD Drum Circle Facilitator & Coach Rhythm With a Purpose Before he fell in love with the transformational impact of coaching, and rhythm facilitation, John spent decades as a degreed percussionist performing jazz and classical music, and the amazing music of cultures from around the world. Rhythms, cycles, and improvisation have always been central to his joy and passion, the spontaneous personal expression that is such a vital part of all living cultures, and indeed, all our lives. As the Manager of Recreational Music Activities for Remo Inc., for 23 years, he created relationships with organizations and individuals, educating and advocating for the use of music for wellbeing in every imaginable population through a global network of partnerships, facilitators, and Remo’s distributor network. Presentations, training, and facilitated experiential activities at conferences and symposia were a central part of his work at Remo, and his passion as well. In addition to one on one work with individuals and organizational leaders, John designed and facilitated team-building, communication and leadership workshops for over 20 years. If you are newly diagnosed, or need a refresher on NET terms and basics, we encourage you to watch Dr. Aman Chauhan’s presentation “NETS 101: Overview of NET Terms & Concepts " or Dr. Chandrasekharan’s presentation “Understanding NET Diagnosis.” The opinions expressed by the guest presenters, as well as the questions asked by the audience, have not been created or suggested by LACNETS or the sponsors of this program. LACNETS does not endorse or promote any of the views, opinions or information provided in this presentation. Audience members should not rely solely on the opinions or information expressed by the guest presenter and should seek guidance and direction from their own medical advisors regarding any choices they make about their health or treatments. THANKS TO OUR SPONSORS REGISTER

See videos of recent educational events on various topics on neuroendocrine cancer Recent Events "Understanding Treatments for Neuroendocrine Tumors and Rationale for Sequencing of Therapy" April 1, 2025 Learn from internationally-renowned neuroendocrine cancer expert Dr. Edward Wolin in a discussion on the latest in neuroendocrine tumor treatments and understanding how to sequence them. Dr. Wolin has pioneered many of the NET treatments including somatostatin analogues (SSAs, sandostatin and octreotide), mTOR inhibitors (i.e. everolimus), anti-angiogenic drugs (i.e. cabozantinib), and peptide receptor radiotherapy (PRRT, i.e. Lutathera). Listen to this insightful presentation and live question and answer session. Watch NCF Regional NET Patient Educational Event March 29, 2025 The Neuroendocrine Cancer Foundation is hosting an in-person NET Educational Event for patients and caregivers in Tucson, Arizona on Saturday, March 29th, from 1:30-6:00 PM. CLOSED "PRRT Nurse's Perspective: What to Expect with PRRT" March 7, 2025 Learn about PRRT from UCLA's Lead PRRT Nurse Linda Gardner. She addresses common questions about what to expect before, during, and after the treatment, as well as concerns about radiation safety. Watch "Deciphering Genetics & Genomics in Neuroendocrine Cancers" with Dr. Kimberly Perez Feb 7, 2025 Learn the latest in genetics and genomics for neuroendocrine cancers from medical oncologist Dr. Kimberly Perez from Dana Farber Cancer Institute (DFCI) in Boston, Massachusetts. Dr. Perez has expertise in hereditary cancer syndromes and deciphers the topics of genetics and genomics. Watch "Understanding GI NETs Found on Endoscopy: Gastric, Duodenal, Colon & Rectal" with Dr. David Metz Jan 28, 2025 Learn from renowned Neuroendocrinologist Dr. David Metz, who discusses neuroendocrine tumors (NETs) found on endoscopy, including gastric, duodenal, colon and rectal NETs. Dr. Metz discusses which NETs can be found on endoscopies and how they are managed and treated. Watch Comprehensive Guide to Lung Neuroendocrine Cancers: From Typical Carcinoids to Small Cell Lung Cancer (SCLC) Tuesday, Dec 10, 2024 Learn all about lung neuroendocrine cancers from neuroendocrine cancer expert Dr. Aman Chauhan, leader of the Neuroendocrine Tumor Program and Co-Director of the Theragnostic Program at the Sylvester Comprehensive Cancer Center, University of Miami. Dr. Chauhan will give a comprehensive guide to lung neuroendocrine cancers ranging from typical carcinoids to small cell lung cancer. WATCH Palliative Care for Neuroendocrine Cancer Thursday, Nov 14, 2024 Learn about Palliative Care: what it is, what it is not, and how it may help those affected by neuroendocrine cancer. Dr. Chandana Banerjee, palliative care and hospice specialist from the City of Hope Cancer Center in Los Angeles, demystifies these topics. WATCH 2024 NET Cancer Day Symposium Saturday, November 9, 2024 Celebrate with us at the 2024 LACNETS NET Cancer Day Symposium in Santa Monica, California on Saturday, November 9th from 8:30 am - 4:30 pm. WATCH Evolving Management of NET Liver Metastases Friday, October 18, 2024 Hear the renowned liver and pancreas surgeon, Dr. Gagandeep “Gaugs” Singh, discuss the evolving algorithms in managing NET liver metastases. Dr. Singh, Chief of Surgical Oncology at City of Hope® Cancer Center in Phoenix, asks the question of whether it is prudent to be aggressive surgically or if it is all about timing and strategy. Regional NET Patient Education Conference Saturday, September 21, 2024 LACNETS is hosting an in-person NET Educational Event for patients and caregivers in Minneapolis, Minnesota, on Saturday, September 21st, from 1:30-5:00 PM. This event was not live-streamed or recorded. Meet the Expert: Dr. Eric Liu Saturday, August 17, 2024 Join LACNETS in Denver, Colorado for an in-person event. Meet NET expert Dr. Eric Liu who will give a broad survey of NET from diagnosis to treatment and philosophy. Engage in an interactive question and answer session with Dr. Liu. It’s a wonderful opportunity to learn, advocate and connect in-person with a NET expert and fellow NET patients and caregivers. 2024 LACNETS Neuroendocrine Tumor Patient Conference Saturday, June 15, 2024 Join us for the biggest LACNETS event of the year featuring more than ten NET experts. This year's theme is Deepening Your Understanding of NETs. WATCH High Grade Neuroendocrine Neoplasms & Small Cell Lung Cancer Tuesday, May 7, 2024 Learn about the latest in high grade neuroendocrine neoplasms and small cell lung cancer with medical oncologist Dr. Aman Chauhan, Leader of the Neuroendocrine Tumor Program and Co-Director of the Theragnostic Program at the Sylvester Comprehensive Cancer Center, University of Miami. 2024 Updates: Neuroendocrine Cancer Clinical Trials Thursday, April 25, 2024 Learn about the latest in clinical trials for neuroendocrine cancer with NET expert Dr. Heloisa Soares, a medical oncologist at the Huntsman Cancer Institute (HCI) at the University of Utah. TKIs: Tyrosine Kinase Inhibitors & Neuroendocrine Tumors Friday, Mar 29, 2024 Learn about Tyrosine Kinase Inhibitors (TKIs), what they are and how they work with NET expert Dr. Jennifer Chan. Dr. Chan is the Vice President of the North American Neuroendocrine Tumor Society (NANETS) and the principal investigator of the CABINET trial. Hear the positive findings from that TKI study using Cabozantinib. She discusses the latest in TKI treatments and how they may be a possible treatment option for many NET patients. LACNETS Educational Event Feb 14, 2024 Join us to learn about Carcinoid Heart Disease from Cardiologist Dr. S. Allen Luis at the Mayo Clinic in Rochester, MN. He will describe the cause and symptoms of carcinoid heart disease and discuss diagnosis, treatment and surveillance. LACNETS Educational Event "PRRT: What We Know, Special Considerations & Clinical Trials" with Dr. Jonathan Strosberg January 11, 2024 Join us on Thursday, January 11th at 9:30 AM Pacific to learn the latest on PRRT with NET expert Dr. Jonathan Strosberg. Dr. Strosberg was the principal investigator of the NETTER-1 study which led to the FDA approval of Lutathera and has authored numerous articles on PRRT. He will discuss the latest in PRRT, including special considerations and current clinical trials. LACNETS Educational Event "Minimally Invasive Treatments for Neuroendocrine Liver Metastases" with Dr. Yilun Koethe Dec 9, 2023 Join us to learn more about minimally invasive liver-directed therapies targeting liver metastases with interventional radiologist Dr. Koethe. She discusses ablations including the recently approved histotripsy and embolizations including bland, chemo, and radioembolization. LACNETS Educational Event "Symptoms Management" with Dr. David Metz Oct 10, 2023 Join LACNETS to hear Neuroendocrinologist Dr. David Metz from University of Pennsylvania discuss symptom management. The presentation will cover carcinoid syndrome, pancreatic enzymes, bile acid secretion, and short bowel syndrome. He will explain current treatments, supplements, and diets that might be helpful to control NET-related symptoms. LACNETS Educational Event "Navigating Clinical Trials: Expectations Vs. Realities" with Taymeyah Al-Toubah, MPH Aug 19, 2023 Hear Taymeyah Al-Toubah, MPH, Senior Research Project Manager at the Neuroendocrine Tumor Program of Moffitt Cancer Center. LACNETS Educational Event "Surgery: The What, Where & When" with Dr. Eric Liu July 7, 2023 Hear NET expert Dr. Eric Liu of Rocky Mountain Cancer Centers discuss “Surgery: The What, Where & When.” 2023 LACNETS Annual NET Patient Conference June 17, 2023 Watch our biggest event of the year with 12 NET experts from North America. WATCH NOW LACNETS E ducational Event Topic: High Grade Neuroendocrine Neoplasms (NEN) May 4, 2023 Join LACNETS on May 4th for an educational event dedicated to high grade neuroendocrine neoplasms (NENs). Medical oncologist Dr. Jason Starr from Mayo Clinic in Jacksonville, Florida, will discuss the management and treatment of high grade NENs, including the latest updates and clinical trials. LACNETS Educational Event: "What's New in PRRT" April 14, 2023 Join Dr. Amir Iravani, a Nuclear Medicine Physician and Theranostics Director at Fred Hutchinson Cancer Center, to hear the latest on Peptide Receptor Radionuclide Therapy (PRRT). Better understand the difference between beta and alpha PRRT, current trials and updates on PRRT for Lung NET, adolescents and dosimetry. LACNETS Educational Event: "Update on NET Clinical Trials" March 10 , 2023 Join Dr. Heloisa Soares, a medical oncologist at the Huntsman Cancer Institute (HCI) at the University of Utah, to hear the latest in NET clinical trials. LACNETS Educational Event: "Genetics of NET: Do I Need Genetic Testing?" Tuesday, February 7 , 2023 Do I need genetic testing? Do my family members need to be tested? What does genetic testing entail? What genetic mutations are possible and what does it mean for my family if I carry a mutation? Join Genetic Counselor Samantha Greenberg of University of Texas, Southwestern for a discussion about genetic testing for NETs. LACNETS Educational Event : "Novel Translational Research for Metastatic NET Patients at the NCI" Friday, January 27, 2023 Join LACNETS for this special educational event. What if you could both undergo surgery for your metastatic disease and also donate your liver tumor to find a cure for NET? Learn how you can contribute to NET research. The NET team at the National Cancer Institute (NCI) will give us a behind-the-scenes look at their innovative NET research. Be inspired by their hard work and dedication to the NET community. LACNETS Educational Event: Focus on Pheochromocytoma/Paraganglioma Wednesday, January 11, 2023 Join LACNETS for a unique webinar with a live presentation of three pheochromocytoma and paraganglioma (PPGL) cases and an engaging panel discussion with experts Dr. Jaydira Del Rivero, Dr. Erik Mittra, and Dr. Karel Pacak. Click here for our video library for more educational videos

The Neuroendocrine Cancer Foundation serves the neuroendocrine cancer (or NET) community by connecting patients, caregivers, and medical professionals. Find educational resources and connect with other NET patients and caregivers. READ MORE Clinical Trials Blog Resources by Topic Podcast UPCOMING EVENTS Apr 29, 2025 Register May 17, 2025 Register Visit our events page for more information >>> Make a Difference Donate today and help us provide support, and information on diagnosis, treatment options, research, and resources for neuroendocrine cancer patients and caregivers. Donate Sign up for email Stay up-to-date with neuroendocrine cancer news, educational information, monthly newsletters and ways to connect with other neuroendocrine cancer patients and caregivers. Make a Difference Donate today and help us provide support, and information on diagnosis, treatment options, research, and resources for NET patients and caregivers. DONATE ABOUT THE NEUROENDOCRINE CANCER FOUNDATION The Neuroendocrine Cancer Foundation provides a community of support and education for neuroendocrine tumor (or neuroendocrine cancer or NET) patients and caregivers. Learn Our educational programs, including webinars , patient education conferences , a video library , podcast , and blog , provide information on diagnosis, treatment options, research and resources. We develop patient-friendly educational content that brings the latest medical information and research studies to NET patients and caregivers. Advocate We advocate f or all people impacted by this rare disease to improve health outcomes through early diagnosis. We raise awareness about neuroendocrine and carcinoid cancers among healthcare professionals and the public. Connect Our inclusive global community includes NET patients, family members, and caregivers. The Neuroendocrine Cancer Foundation makes it possible for patients to share experiences, encouragement, and hope through support groups , Health Coaching , and NETCONNECT , a buddy program connecting a newly-diagnosed NET patient with a long-time patient. Seven Facts About NET Neuroendocrine cancer is also known as neuroendocrine tumor, or NET. NET is a rare cancer. In the United States, 7 in 100,000 people are diagnosed per year. NET can affect neuroendocrine cells throughout the body. NET is a difficult cancer to diagnose. Some (but not all) NET patients have symptoms from their cancer. The cause of NET is unknown. Seeking the opinion of a NET specialist is important for all NET patients. LATEST ON CLINICAL TRIALS Clinical Trials News Play Video Play Video 05:30 Dr. Halfdanarson on ITM’s COMPETE Trial • 2025 ENETS • Neuroendocrine Cancer Foundation NANETS President Emeritus Dr. Thor Halfdanarson discussed the positive results from ITM’s Phase 3 COMPETE Trial at the 2025 ENETS Annual Medical and Scientific Conference in Krakow, Poland. The COMPETE trial was the first prospective, randomized phase 3 study comparing PRRT with an active treatment (everolimus or afinitor). For more information, visit https://www.ncf.net/clinical-trials. Play Video Play Video 05:27 Dr. Jennifer Chan Discusses Results of CABINET Trial (Cabozantinib) as Effective Treatment at ESMO24 Watch #LACNETS' exclusive view with incoming NANETS president Dr. Jennifer Chan at ESMO Congress 2024 (#ESMO24) in Barcelona, Spain, explaining the updated results of the CABINET trial evaluating Cabozantinib in Advanced Neuroendocrine Tumors. https://www.lacnets.org/post/positive-results-of-the-cabinet-trial-show-cabozantinib-as-a-new-effective-treatment-in-advanced-n Play Video Play Video 04:44 Dr. Aman Chauhan About the Most Exciting Progress in the Neuroendocrine Cancer Field @ NANETS Miami In this exclusive interview at NANETS Regional in Miami, NET expert Dr. Aman Chauhan from Sylvester Comprehensive Cancer Center shares the recent advances he's most excited about in the neuroendocrine cancer field. @SylvesterCancer @AmanChauhanMD @CarcinoidNETs @HealingNET1 @netcancerday @CureNETs @PheoPara #NETsMiami Play Video Play Video 03:51 Breaking News: NETTER-2 Trial Supports Lutathera® as 1st Line Treatment - Dr. Singh Explains The NETTER-2 phase 3 trial results show Lutathera® may be offered as first-line treatment for newly diagnosed grade 2 and 3 advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs). When compared to long-acting octreotide, Lutathera® reduced the risk of disease progression or death by 72% in patients with somatostatin receptors. “These positive results for Lutathera are practice-changing and offer new first-line treatment data for patients who have a significant unmet need. This study confirms the clinical benefit of first-line radioligand therapy (RLT) for newly diagnosed patients living with these types of advanced GEP-NETs. These findings should instill confidence among physicians in using Lutathera as a first-line treatment for patients with this life-threatening type of cancer.” — Dr. Simron Singh, NET expert, Sunnybrook Health Sciences Centre, Ontario, Canada. Read the full Novartis Press Release: https://www.novartis.com/news/media-releases/novartis-lutathera-significantly-reduced-risk-disease-progression-or-death-72-first-line-treatment-patients-advanced-gastroenteropancreatic-neuroendocrine-tumors Play Video Play Video 04:05 Dr. Soulen Talks About 2023 Highlights and His Hopes for 2024 Director of Programs and Outreach Lisa Yen interviews Dr Michael Soulen, Interventional Radiologist at Penn. He talks about the highlights of 2023 and shares his hopes for 2024. Play Video Play Video 02:14 Dr. Kunz Shares 2023 Highlights and Her Hopes for 2024 Director of Programs and Outreach Lisa Yen interviews NANETS Past President, Dr. Pamela Kunz. She talks about the highlights of 2023 and shares her hopes for 2024. Play Video Play Video 04:01 Dr. Strosberg Shares 2023 Highlights and Hopes for 2024 Director of Programs and Outreach Lisa Yen interviews Dr. Jonathan Strosberg, Medical Oncologist at Moffitt. He talks about the highlights of 2023 and shares his hopes for 2024. Play Video Play Video 03:40 Dr. Halfdanarson Shares 2023 Highlights and His Hopes for 2024 Director of Programs and Outreach Lisa Yen interviews NANETS President Dr. Thor Halfdanarson. He talks about the highlights of 2023 and shares his hopes for 2024. Breaking News: NETTER-2 Trial Supports Lutathera® as 1st Line Treatment >>> Dr. Jennifer Chan Announces the CABINET Trial Data on Cabozantinib >>> Clinical Trials Guide LATEST FROM NCF WATCH 400+ Videos on Various Topics 2024 NET Cancer Day Symposium LISTEN Hear Experts Answer Top 10 Questions on Each Topic "Against the Tide: The Mary Donlevy Story" TAKE ACTION Learn About Active Clinical Trials RECENT EDUCATIONAL EVENTS Play Video Play Video 01:26:11 "Palliative Care for Neuroendocrine Cancer" Dr. Chandana Banerjee • 2024 #LACNETS Educational Event Learn about Palliative Care: what it is, what it is not, and how it may help those affected by neuroendocrine cancer. Dr. Chandana Banerjee, a palliative care and hospice specialist from the City of Hope Cancer Center in Los Angeles, demystifies these topics. Visit LACNETS.org for more information. Play Video Play Video 01:35:06 "Evolving Management of NET Liver Metastases" Dr. Gagandeep Singh • 2024 #LACNETS Educational Event Join us to hear renowned liver and pancreas surgeon Dr. Gagandeep “Gaugs” Singh discuss the evolving algorithms in the management of NET liver metastases. Dr. Singh, Chief of Surgical Oncology at City of Hope® Cancer Center in Phoenix, asks the question of whether it is prudent to be aggressive surgically or if it is all about timing and strategy. For more information, visit LACNETS.org. Play Video Play Video 01:27:16 "2024 Updates on Clinical Trials in Neuroendocrine Tumors" • 2024 LACNETS Event • April 25, 2024 Join us to learn about the latest in clinical trials for neuroendocrine tumors with NET expert Dr. Heloisa Soares, a medical oncologist at the Huntsman Cancer Institute (HCI) at the University of Utah. For more information about Clinical Trials, visit https://www.lacnets.org/clinical-trials. For more information, visit LACNETS.org. Play Video Play Video 01:18:47 "TKIs: Tyrosine Kinase Inhibitors & Neuroendocrine Tumors" • 2024 LACNETS Event • March 29, 2024 Learn about Tyrosine Kinase Inhibitors (TKIs), what they are and how they work with NET expert Dr. Jennifer Chan. Dr. Chan is the Vice President of the North American Neuroendocrine Tumor Society (NANETS) and the principal investigator of the CABINET trial. Hear the positive findings from that TKI study using Cabozantinib. She will discuss the latest in TKI treatments and how they may be a possible treatment option for many NET patients. For more information, visit lacnets.org. Play Video Play Video 01:29:36 "Carcinoid Heart Disease" • 2024 LACNETS Event • Feb 14, 2024 Learn about Carcinoid Heart Disease from Cardiologist Dr. S. Allen Luis, at the Mayo Clinic in Rochester, MN. He will describe the cause and symptoms of carcinoid heart disease and discuss diagnosis, treatment and surveillance. Visit LACNETS.org for more information. Play Video Play Video 01:12:47 "PRRT: What We Know, Special Considerations & Clinical Trials" with Dr. Strosberg • Jan 11, 2024 Learn the latest on PRRT with NET expert Dr. Jonathan Strosberg. Dr Strosberg was the principal investigator of the NETTER-1 study which led to the FDA approval of Lutathera and has authored numerous articles on PRRT. He will discuss the latest in PRRT, including special considerations and current clinical trials. Visit LACNETS.org for more information. Play Video Play Video 01:19:50 "Minimally Invasive Treatments for Neuroendocrine Liver Metastases" • Dr. Yilun Koethe • Dec 9, 2023 "Minimally Invasive Treatments for Neuroendocrine Liver Metastases" with Dr. Yilun Koethe, Interventional Radiologist, TRG Imaging. Learn more about minimally invasive liver directed therapies targeting liver metastases with interventional radiologist Dr. Koethe. She discusses ablations including the recently approved histotripsy and embolizations including bland, chemo and radioembolization. ~ Visit LACNETS.org for more information. Play Video Play Video 01:33:48 LACNETS • "Symptom Management" with Dr. David Metz • Oct 2023 Join LACNETS to hear Neuroendocrinologist, Dr. David Metz from University of Pennsylvania discuss symptom management. The presentation will cover carcinoid syndrome, pancreatic enzymes, bile acid secretion, and short bowel syndrome. He will explain current treatments, supplements, and diets that might be helpful to control NET-related symptoms. For more information, visit LACNETS.org. LATEST PODCAST EPISODES RESOURCES & INFORMATION FOR YOU Meetings Register for the upcoming educational webinars and programs Support Groups Learn about the NET patient and caregiver support groups Podcast A podcast series where neuroendocrine tumor (NET) experts answer the top 10 FAQs on various NET topics Resources Check our resource navigation guide which covers various topics from treatment options to wellness NETCONNECT Program A peer support system that connects newly-diagnosed patients with mentors Newly Diagnosed Newly-diagnosed NET patients can begin exploring here for resources and support NET VITALS A tool for patients and healthcare professionals to share vital information about a patient’s neuroendocrine cancer Clinical Trials Explore open clinical trials here Blog Read about various NET topics, inspiring survival stories, and tips to live fully and richly with cancer Patient & Caregiver Stories Find inspiration and hope from NET patient and caregiver stories Spanish Resources Explore Spanish-language resources for NET patients and caregivers Health Coaching Learn how you can receive one-on-one coaching sessions available to NET patients and caregivers I was officially diagnosed on June 29, 2022. I didn’t even know NETs existed. And today...less than a month later, I’ve learned so much thanks to the incredible resources that exist as a result of the beautiful NETs community. The resources available, especially the videos from the (Neuroendocrine Cancer Foundation) and the NET VITALS document, are so life-giving and helpful for the newly diagnosed. The Neuroendocrine Cancer Foundation contributes so much useful information to the NET community. — NET Patient

WEEKLY Virtual NET Support Group Meetings April 23, 2025 Wednesday, 12:00 - 1:30 PM Pacific Register We provide a welcoming space to come together virtually for knowledge sharing and community support. The focus of the meeting is to connect with others living with, or supporting someone living with, Neuroendocrine Tumor (NET). Both patients & caregivers discuss treatments, symptoms, living well and information uniquely related to this disease. This group is open to NET patients and caregivers. Join us via Zoom every Wednesday at 12 -1:30 PM Pacific Time. Before the live support meeting, please be sure to download Zoom on your preferred device: zoom.us/download Click here to watch a tutorial on how to download and join Zoom. *Please note all Zoom meeting details will be emailed to you within 24 hours of your registration. Questions? Email events@ncf.net . *Limited spots available. NET Support Group Registratin Register THANKS TO OUR SUPPORTERS

PRRT Resources CLINICAL TRIALS Peptide Receptor Radionuclide Therapy (PRRT) Active Clinical Trials Explore Clinical Trials EDUCATIONAL WEBINARS "PRRT Nurse's Perspective: What to Expect With PRRT" March 7, 2025 Click here to download the transcript >>> Learn about PRRT from UCLA's Lead PRRT Nurse Linda Gardner. She addresses common questions about what to expect before, during, and after the treatment, as well as concerns about radiation safety. Watch here "Understanding PRRT" - 2024 LACNETS Neuroendocrine Tumor Patient Conference June 15, 2024 LACNETS Educational Event January 11, 2024 Learn the latest on PRRT with NET expert Dr. Jonathan Strosberg. Dr. Strosberg was the principal investigator of the NETTER-1 study which led to the FDA approval of Lutathera and has authored numerous articles on PRRT. He will discuss the latest in PRRT, including special considerations and current clinical trials. Watch here "The Latest in PRRT" with Carina Mari Aparici, MD Watch "The Latest in PRRT" with Dr. Carina Mari Aparici. This presentation is part of the 2023 LACNETS Neuroendocrine Tumor Patient Education Conference held on June 17, 2023. Watch here "What's New in PRRT" with Amir Iravani, MD Nuclear Medicine Physician and Theranostics Director at Fred Hutchinson Cancer Center, Dr. Amir Iravani, shares the latest on Peptide Receptor Radionuclide Therapy (PRRT). Better understand the difference between beta and alpha PRRT, current trials and updates on PRRT for Lung NET, adolescents and dosimetry. Watch here "The Latest in NET Imaging & PRRT" with Thomas Hope, MD NET expert and radiologist Dr. Thomas Hope of UCSF addresses the latest in NET imaging and PRRT. Watch here "Future of PRRT" with Erik S. Mittra, MD, PhD Nuclear Medicine Physician Dr. Erik Mittra provides an update on PRRT. Plus, hear from a NET patient who has received multiple rounds of PRRT treatments. Watch here "Exciting Advances in NET Management: Cu64 DOTATATE & Alpha PRRT" with Ebrahim S. Delpassand, M.D., F.A.C.N.M. Nuclear medicine specialist Dr. Delpassand provides an update on the exciting advances in NET Management including Cu64 DOTATATE & Alpha PRRT. Watch here Click here for our full PRRT video playlist. READ NETTER-2 Study Results: Looking Beyond The Headlines New Article: Sequencing of Somatostatin-Receptor–Based Therapies in Neuroendocrine Tumor Patients This is an excellent review article giving a thorough overview of the evidence behind somatostatin receptor targeted therapies, which includes long-acting somatostatin analogues (SSAs) octreotide LAR and lanreotide, and radiolabeled SSAs, otherwise known as PRRT. The article offers insights regarding optimal patient selection, assessment of benefit versus risk, and treatment sequencing. PRRT PATIENT/CAREGIVER STORIES Patient Story: NET Patient shares his experience with PRRT (LACNETS) Play Video Patient Story: NET Patient shares her experience with PRRT (LACNETS) Play Video Patient & Caregiver Story: NET patient & caregiver share about their experience with PRRT (LACNETS) Play Video Patient Story: NET Patient shares her experience with Alpha PRRT Play Video PRRT Patient/Caregiver Stories Watch Now Share Whole Channel This Video Facebook Twitter Pinterest Tumblr Copy Link Link Copied Share Channel Info Close PODCAST What is PRRT? How is it different from the more commonly used radiation treatment? What are the possible side effects? Dr. Riham El Khouli from the University of Kentucky in Lexington discusses common questions and concerns about PRRT and shares some of the latest advances. Listen here Administrative Nurse Lindy Gardner of UCLA Health answers 10 common questions about the before, during and after of PRRT. Listen here Nuclear Medicine Physician Dr. Martin Auerbach of UCLA Health answers 10 common questions about the decision-making process of PRRT. Listen here Patient advocate Josh Mailman answers ten common questions about the past, present, and future of PRRT. Listen here BLOG POSTS Read here Read here Read here PRRT CLINICAL TRIALS ITM “COMPOSE” PHASE III CLINICAL TRIAL: 177 LU-EDOTREOTIDE VS. BEST STANDARD OF CARE IN WELL-DIFFERENTIATED AGGRESSIVE G2 & G3 GEP-NETS COMPOSE is an international phase III clinical study to evaluate the efficacy, safety and impact on quality of life of Targeted Radionuclide Therapy (PRRT) with no-carrier-added lutetium-177-edotreotide (n.c.a. 177Lu-edotreotide) compared to a standard therapy with either CAPTEM or everolimus or FOLFOX, in patients with well-differentiated advanced Grade 2 and Grade 3, somatostatin receptor-positive (SSTR+) neuroendocrine tumors of gastroenteric or pancreatic origin (G2 and G3 GEP-NETs). The study is being conducted predominantly in Europe, North America, India and Australia, in approximately 10 countries and 40 sites. Learn more and join the study here. ALPHA PRRT PHASE 1B/3 TRIAL - GRADE 1-2 GEP-NETS WITH PROGRESSION AFTER PREVIOUS LUTATHERA TREATMENT RayzeBio is sponsoring the ACTION-1 study, a phase 1b/3 open-label study of 225Ac-DOTATATE (RYZ101) compared with standard of care therapy in patients with inoperable, advanced, SSTR+ well-differentiated GEP-NET that has progressed following treatment with 177Lu-DOTATATE/TOC. The phase 3 portion is currently enrolling. More information on this trial can be found here. MORE PRRT CLINICAL TRIALS Alpha PRRT with Pb212 (Alphamedix) PRRT for lung NETs PRRT for adolescents Lutathera PRRT plus olaparib (as a radiosensitizer) Lutathera PRRT plus M3814 Lutathera PRRT vs CAPTEM for advanced PNET NETTER 2 = PRRT as 1st line in Grade 2 or 3 GEP-NET patients (recently completed enrollment) This is not a comprehensive list of NET clinical trials. For more information about available clinical trials, go to www.clinicaltrials.gov . READING MATERIALS “Your Guide to NETSPOT®” by Advanced Accelerator Applications Download here “Your Guide to Lutathera Treatment” by Advanced Accelerator Applications Download here Key Facts about PRRT by Advanced Accelerator Applications Download here AAA PATIENT CONNECT by Advanced Accelerator Applications Download here Detectnet Patient Brochure by Curium Download here NANETS NET GUIDELINES BY TOPIC 2017 (Joint with SNMMI) Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors 2020 NANETS/SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy Click here for Imaging Resources This is for informational use only. LACNETS is not endorsing or recommending any particular treatment or trials. LACNETS encourages you to discuss your individual needs and options with your medical team. For more information about available clinical trials, go to www.clinicaltrials.gov .

< Back to the upcoming events page Download the Transcript Here >>> ABOUT Learn about PRRT from UCLA's Lead PRRT Nurse Linda Gardner. She addresses common questions about what to expect before, during, and after the treatment, as well as concerns about radiation safety. ABOUT LINDA GARDNER, MSN, RN, VA-BC LINDA (LINDY) GARDNER, MSN, RN, VA-BC Lead Nurse, Nuclear Medicine UCLA Health Lindy has over two decades of Interventional Radiology experience prior to transitioning over to Nuclear Medicine in March of 2017. She obtained her RN qualification in 1993 from John Moores University of Liverpool, (LJMU) United Kingdom, she is a graduate from the University Of Dundee, Scotland where she received her Bachelors, and Master’s of Science in Nursing. In her Nuclear Medicine role Lindy is the lead nurse for the Peptide Receptor Radionuclide Therapy (PRRT) program, from the expanded access program (EAP) through to the FDA approved commercial program. She has presented this program to a national and international audience; her skills are utilized as an expert liaison for institutions commencing the PRRT program, focusing on the patient experience, education, and therapy administration. Lindy is the nursing pillar lead for The International Center for Precision Oncology foundation (ICPO), with her focus on education, support and navigation for the NET patient journey. She is also the lead nurse for Radioligand Therapy (RLT) for prostate cancer within Theranostics at UCLA, covering both clinical application and research. Lindy is a member of the Association for Radiologic and Imaging Nursing (ARIN), and the Association for Vascular Access (AVA), holding her board certification in vascular access (VACC). She serves as a member of the Neuroendocrine Cancer Foundation Medical Advisory Committee and The Healing NET Scientific Advisory Committee. The opinions expressed by the guest presenters, as well as the questions asked by the audience, have not been created or suggested by the Neuroendocrine Cancer Foundation or the sponsors of this program. The Neuroendocrine Cancer Foundation does not endorse or promote any of the views, opinions or information provided in this presentation. Audience members should not rely solely on the opinions or information expressed by the guest presenter and should seek guidance and direction from their own medical advisors regarding any choices they make about their health or treatments. THANKS TO OUR SPONSORS

< Back to the upcoming events page ABOUT Learn the latest in genetics and genomics for neuroendocrine cancers from medical oncologist Dr. Kimberly Perez from Dana Farber Cancer Institute (DFCI) in Boston, Massachusetts. Dr. Perez has expertise in hereditary cancer syndromes and deciphers the topics of genetics and genomics. ABOUT DR. PEREZ Kim Perez, MD Medical Oncologist D ana Farber Cancer Institute (DFCI) Dr. Kimberly Perez, MD is a member of the Dana-Farber Cancer Institute/Harvard Cancer Center Gastrointestinal Oncology and Cancer Genetics and Prevention disease centers. She is a Senior Physician in Medical Oncology at Dana-Farber Cancer Institute, an Associate Physician in Medical Oncology at Brigham and Women’s Hospital, co-Director of the DFCI Gastrointestinal Clinical Trials program, and an Assistant Professor of Medicine at Harvard Medical School. She received her undergraduate training at Georgetown University in Washington DC and received her medical doctorate from George Washington University in Washington DC. She completed her residency and fellowship training at Rhode Island Hospital in 2010. After completing her fellowship, she joined the medical faculty at Warren Alpert School of Medicine at Brown University and served as a Gastrointestinal Oncologist at the Comprehensive Cancer Center at Rhode Island Hospital. She joined the faculty at the Dana-Farber Cancer Institute in 2015 as a medical oncology physician-scientist who provides patient care and conducts clinical research of novel therapies for patients diagnosed with gastrointestinal cancers and inherited cancer syndromes. Since she joined the faculty, she was designated a Hale Family Center for Pancreatic Cancer Research Clinical Investigator and has developed and led investigator-initiated bench to clinic multi-institutional clinical trials for patients with pancreatic adenocarcinoma. Within the Neuroendocrine and Carcinoid program, she has led multi-institutional clinical trials, translational efforts, and served and led national therapeutic guideline efforts. Dr. Perez is a medical oncology physician-scientist who provides patient care and conducts clinical research of novel therapies for patients diagnosed with gastrointestinal cancers and associated hereditary cancer syndromes. Since she joined the faculty at Harvard Medical School and the Dana-Farber Cancer Institute in 2015, she has developed and led investigator-initiated clinical trials investigating novel therapies for patients with pancreatic adenocarcinoma and neuroendocrine tumors. The opinions expressed by the guest presenters, as well as the questions asked by the audience, have not been created or suggested by LACNETS or the sponsors of this program. LACNETS does not endorse or promote any of the views, opinions or information provided in this presentation. Audience members should not rely solely on the opinions or information expressed by the guest presenter and should seek guidance and direction from their own medical advisors regarding any choices they make about their health or treatments.

< Back to the upcoming events page Download the Transcript Here >>> ABOUT Learn from internationally-renowned neuroendocrine cancer expert Dr. Edward Wolin in a discussion on the latest in neuroendocrine tumor treatments and understanding how to sequence them. Dr. Wolin has pioneered many of the NET treatments including somatostatin analogues (SSAs, sandostatin and octreotide), mTOR inhibitors (i.e. everolimus), anti-angiogenic drugs (i.e. cabozantinib), and peptide receptor radiotherapy (PRRT, i.e. Lutathera). Join us for an insightful presentation and live question and answer session. ABOUT DR. EDWARD WOLIN DR. Edward Wolin Professor of Medicine, Medical Oncology, Icahn School of Medicine Director, Center for Carcinoid and Neuroendocrine Tumors Tisch Cancer Institute, Mount Sinai Health System Dr. Edward M. Wolin is an internationally renowned authority on neuroendocrine tumors. Dr. Wolin is the Director of the Center for Carcinoid and Neuroendocrine Tumors at the Tisch Cancer Institute at Mount Sinai and Professor of Medicine, Medical Oncology at the Icahn School of Medicine at Mount Sinai. The multidisciplinary Center for Carcinoid and Neuroendocrine Tumors features a robust research program with clinical trials aimed at finding the most effective treatments, including immunotherapy, biologic agents, targeted radiation therapy, and new approaches in molecular imaging for diagnosis. Dr. Wolin has pioneered innovative therapies with novel somatostatin analogs, mTOR inhibitors, anti-angiogenic drugs, and peptide receptor radiotherapy. Prior to joining Mount Sinai, Dr. Wolin was Director of the Neuroendocrine Tumor Program at Montefiore Einstein Cancer Center. Previously, he worked for more than two decades with Cedars-Sinai Medical Center in Los Angeles, where he founded and directed one of the largest Carcinoid and Neuroendocrine Tumor Programs in the country, and subsequently directed the Neuroendocrine Tumor Program at University of Kentucky. Dr. Wolin is also the Co-Medical Director for the Carcinoid Cancer Foundation and is on the Carcinoid Cancer Research Grants Scientific Review Committee for the American Association for Cancer Research. He has published in many prestigious journals, including the New England Journal of Medicine and Journal of Clinical Oncology, and is a reviewer for numerous journals, including Journal of Clinical Oncology, Molecular Cancer Therapeutics, Clinical Cancer Research, and The Lancet Oncology. During Dr. Wolin’s two decades at Cedars-Sinai Medical Center in Los Angeles, he developed a close friendship with LACNETS founder Giovanna Joyce Imbesi. Dr. Wolin was instrumental in the co-founding and development of LACNETS. LACNETS has always been very dear to his heart and he cherishes and honors the memory of Giovanna. Dr. Wolin earned his medical degree from Yale School of Medicine. He completed both his residency in internal medicine and fellowship in medical oncology at Stanford University Hospital. He was also a clinical fellow at the National Cancer Institute of the National Institutes of Health. Dr. Wolin is board certified in internal medicine and medical oncology. T he opinions expressed by the guest presenters, as well as the questions asked by the audience, have not been created or suggested by the Neuroendocrine Cancer Foundation or the sponsors of this program. The Neuroendocrine Cancer Foundation does not endorse or promote any of the views, opinions or information provided in this presentation. Audience members should not rely solely on the opinions or information expressed by the guest presenter and should seek guidance and direction from their own medical advisors regarding any choices they make about their health or treatments. THANKS TO OUR SPONSORS

< Back to the upcoming events page REGISTER ABOUT The Neuroendocrine Cancer Foundation is hosting an in-person Neuroendocrine Cancer Educational Event for patients and caregivers in Santa Monica, California on Saturday, May 17th, from 3:45 -7:30 PM. Hear four presentations from neuroendocrine cancer experts. Engage in two Q&A sessions. Listen to a patient story. Learn about liver-directed therapy, systemic therapy, PRRT, and clinical trials. Network with other patients and caregivers. A light dinner will be served. There is no cost to attend. This event is made possible by the generosity of donors and sponsors. Special thanks to our host, Dr. Alexandra Gangi (Cedar-Sinai Medical Center). This event will not be broadcast or recorded. Note: The Neuroendocrine Cancer Foundation was formerly known as LACNETS. Read the full announcement here >>> LOCATION Sandbourne Santa Monica 1740 Ocean Avenue Santa Monica, CA 90401 THANKS TO OUR SUPPORTERS AGENDA Time Topic Speaker 3:45 - 4:15 PM Check-in 4:15 - 4:25 PM Welcome & Introductions Neuroendocrine Cancer Foundation Team 4:25 - 4:30 PM Patient Story 4:30 - 4:45 PM Liver-Directed Therapy: Understanding Minimally Invasive Options to Treat Liver Tumors Gabriel Lipshutz, MD, Interventional Radiologist, Cedars-Sinai 4:45 - 5 PM Systemic Therapy for NETs: Medical Options for Metastatic Tumors J. Randolph Hecht, MD, UCLA 5 - 5:45 PM Q&A with Expert Panel Callisia Clark, MD, Julie Hallet, MD, Gabriel Lipshutz, MD, Randolph Hecht, MD; Moderated by Alexandra Gangi, MD 5:45 - 6:30 PM Break & Dinner 6:30 - 6:45 PM PRRT: Current & New Trends Thorvardur Halfdanarson, MD, Medical Oncologist, Mayo Clinic 6:45 - 7:00 PM Clinical Trials: The Latest & Greatest Heloisa Soares, MD, Huntsman Cancer Institute 7:00 - 7:30 PM Q&A with Expert Panel Thorvardur Halfdanarson, MD, Heloisa Soares, MD, Alexandra Gangi, MD; Moderated by Andrew Hendifar 7:30 PM Closing Neuroendocrine Cancer Foundation Team This agenda is subject to change. Please check this page for the most updated agenda. REGISTER ABOUT OUR SPEAKERS Callisia Clark, MD, MS, FACS, FSSO Chief of MCW Surgery Medical College of Wisconsin Panelist Dr. Clarke is Chief of Surgical Oncology and Associate Professor of Surgery at the Medical College of Wisconsin with a focus on tumors of the upper gastrointestinal tract, sarcomas, melanomas and regional therapies for advanced malignancies. She specializes in hepato-pancreatic-biliary malignancies, primary and metastatic neuroendocrine tumors, melanoma and sarcoma. Her research efforts focus on personalized cancer care and targeted approaches in pancreatic neuroendocrine tumors. Dr. Clarke also serves on the Executive Committee of the Association for Academic Surgery and is the Chair of the North American Neuroendocrine Tumor Society (NANETS) Mentoring and Early Career Development Committee. President Biden recently announced she will be appointed as a Member of the National Cancer Advisory Board. Dr. Clarke will play a key role in guiding the Director of the National Cancer Institute in setting the course for the national cancer research program and help advance breakthroughs to prevent, detect, and treat diseases like cancer. Alexandra Gangi, MD Surgical Oncologist Cedars-Sinai Medical Center Moderator/Panelist Dr. Alexandra Gangi is a board-certified surgical oncologist at Cedars-Sinai Medical Center in Los Angeles. Dr. Gangi completed a general surgical residency at Cedars-Sinai and completed her surgical oncology fellowship at the H. Lee Moffitt Cancer Center in Tampa, Florida. She currently serves as the director of the Gastrointestinal Tumor and Cancer Regional Therapies Programs with specialization in Pancreatic and GI Neuroendocrine tumors, Metastatic colorectal cancer, and Peritoneal Surface Malignancies. Her research focuses on understanding GEPNET heterogeneity between and within tumors subtypes and mechanisms of chemotherapy induced liver injury. Thorvardur Halfdanarson, MD Medical Oncologist Mayo Clinic Speaker/Panelist Thor R. Halfdanarson, M.D., is a medical oncologist and Professor of Oncology at Mayo Clinic who specializes in the management of patients with neuroendocrine neoplasms, gastrointestinal malignancies and unknown primary malignancies. His specific research interests include the epidemiology, risk factors and treatment of neuroendocrine tumors and neuroendocrine carcinoma and improving outcomes for pancreatic adenocarcinoma and rare types of pancreatic tumors. He is a principal investigator and co-investigator for multiple industry-sponsored and cooperative group clinical trials. Dr. Halfdanarson holds several leadership positions within Mayo Clinic Comprehensive Cancer Center. He is chair of the Hepato-Pancreatico-Biliary Cancer Disease Group and co-chair of the Pancreatic/Neuroendocrine Tumor Board. He is associate medical director of the Cancer Clinical Trials Office in Rochester, Minnesota, co-chair of the Feasibility Committee, and a member of the Clinical Research Leadership Committee. He also represents Mayo Clinic on the Neuroendocrine Tumors Guidelines Panel of the National Comprehensive Cancer Network (NCCN). Dr. Halfdanarson is the President Emeritus for the North American Neuroendocrine Tumor Society (NANETS). Julie Hallet, MD, MSc., FRCSC Surgical Oncologist Sunnybrook Health Sciences Center Panelist Dr. Hallet is an Associate Professor of Surgery at the University of Toronto and a Surgical Oncologist with a clinical practice devoted to hepato-biliary, pancreatic and upper gastrointestinal malignancies at the Odette Cancer Centre - Sunnybrook Health Sciences Centre. Her practice further focuses on neuroendocrine tumors as part of the Susan Leslie Multidisciplinary Clinic for Neuroendocrine Tumors. She completed general surgery residency and MSc in clinical epidemiology at Université Laval in Québec City, followed by a Surgical Oncology and hepato-pancreatico-biliary clinical fellowship at the University of Toronto, and additional training in advanced minimally invasive surgery at the Institut de recherche contre les cancers de l’appareil digestif (IRCAD) in Strasbourg, France. Dr. Hallet’s research focuses on health services research to improve the fidelity of care delivery in cancer surgery through patient-centred quality monitoring, high-performing team care models, and patient risk-communication support. Her work has obtained over $10 millions in peer-reviewed operating grants and led to more than 220 peer-reviewed publications. J. Randolph Hecht, MD Medical Oncologist UCLA Health Speaker/Panelist Dr. Hecht is a Professor of Clinical Medicine in the David Geffen School of Medicine at UCLA School of Medicine. He holds the Carol and Saul Rosenzweig Chair for Cancer Therapies Development and is the Director of the UCLA Gastrointestinal Oncology Program. Dr. Hecht attended medical school at Eastern Virginia Medical School. He took his internal medicine residency at Northwestern and completed fellowships in gastroenterology research at the University of Chicago, and in gastroenterology and medical oncology at UCLA. Dr. Hecht is an internationally known clinical and translational researcher in the field of gastrointestinal cancers. He has published widely on the molecular biology, early detection, and treatment of gastrointestinal malignancies. He has lead and is currently directing small trials with new molecules as well as large international randomized trials. Current ongoing research includes preclinical models of therapy with biological agents, early studies with gene therapy vectors and tyrosine kinase inhibitors, and leading phase II and phase III trials with novel agents. Andrew Hendifar, MD Medical Oncologist Cedars-Sinai Medical Center Moderator The current research focus of Andrew Hendifar, MD, is on developing new therapies for pancreatic cancer and neuroendocrine tumors. Dr. Hendifar has helped form multidisciplinary teams that specialize in the treatments of pancreatic cancer, and carcinoid and neuroendocrine tumors. Dr. Hendifar is the primary investigator for several groundbreaking therapies, including radioimmunotherapy for neuroendocrine tumors, anti-inflammatory therapy for pancreatic cancer and novel approaches to cancer cachexia. His national roles include SWOG GI Committee Member and a member of NIH Neuroendocrine Tumor Task Force. He also serves as the steering committee member for the Precision Promise Consortium and chairs the associated Supportive Care Committee. At Cedars-Sinai, he leads the Gastrointestinal Disease Research Group and is the founding Director of the Hematology and Oncology Fellowship Program. J. Gabriel Lipshutz, MD Interventional Radiologist Cedars-Sinai Medical Center Speaker/Panelist H. Gabriel Lipshutz, MD is a board-certified, fellowship-trained vascular and interventional radiologist with the Cedars-Sinai S. Mark Taper Foundation Imaging Center. Dr. Lipshutz performs all peripheral endovascular and interventional procedures including embolizations and minimally invasive oncological treatments (chemoembolization, Y-90 radioembolization, RFA, cryoablation, microwave ablation, and irreversible electroporation (IRE). His responsibilities include consultation and treatment of outpatients and inpatients, including the evaluation of patients in the IR outpatient clinic. After earning his bachelor's degree from Wesleyan University, Dr. Lipshutz earned his medical degree from the University of California, San Francisco. He completed his internship in internal medicine at the University of Washington, his radiology residency at the Oregon Health and Sciences University, and his fellowship in interventional radiology at UCLA. Dr. Heloisa Soares Medical Oncologist Huntsman Cancer Institute Speaker/Panelist Dr. Heloisa Soares is a medical oncologist who focuses on neuroendocrine cancers. She is an associate professor at the Huntsman Cancer Institute (HCI) at the University of Utah, where she is also the Medical Director for the Clinical Trials Office. Nationally, she serves as the NCI NET task force co-chair and the chair of the North American Neuroendocrine Tumor Society (NANETS) inaugural NET Patient Action Team of the NETPact Committee. She also recently served as a member of the directors for NANETS. Dr. Soares is a passionate advocate for patients. You can follow her on Twitter at @helops79.

<< Go back to the Podcast page EPISODE 43: CARCINOID HEART SYNDROME Download a Transcript of this Episode >>> ABOUT THIS EPISODE What is Carcinoid Heart Disease (CHD)? Which NET patients develop CHD? Retired cardiologist and carcinoid heart disease specialist Dr. Jerome Zacks provides an overview on CHD and describes the appropriate screening, diagnosis, and treatment. MEET DR. JEROME ZACKS Dr. Jerome Zacks is a Cardiologist/Carcinoid Heart Disease Specialist; retired since December of 2021; but remain active as Associate Clinical Professor of Medicine at the Icahn Medical School at Mount Sinai in New York City and founding member of the Center for Carcinoid and Neuroendocrine Tumors at the Icahn Medical School at Mount Sinai; founder of the Carcinoid Heart Center; formerly on the Medical Advisory Board of the Carcinoid Cancer Foundation; currently head the Electrocardiography course for the 4th Year Medical Student elective at the Mt. Sinai Medical Center which has resulted in an international reputation among students seeking Cardiology training in the United States. He has expertise in matters of health care Insurance Carriers' theft of funds from the Medicare program, has studied patterns of abuse in the Medicaid program and has extensive knowledge of pharmaceutical company abusive practices. Dr Zacks continues to devote time to the care of patients with Carcinoid Heart Disease. He has served as a member of the Guidelines Committees of the European Neuroendocrine Tumor Society (ENETS) and of the North American Neuroendocrine Tumor Society (NANETS). He developed a new approach to compression stockings for patients with leg edema; he was granted a patent for this innovation. He has authored two national petitions urging Congress to mandate that any health care professional who uses one’s license, in making decisions which influence a patient’s care, be held to the SAME STANDARD OF CARE as the patient’s treating professional. (These two petitions were blocked by Senator Cory Booker.) In his role as patients’ physician, he has attempted to remove barriers of communication. His business card includes his personal mobile phone number as well as his email address and website information; He encourages patients to phone for immediate answers to urgent matters. Along with his wife, Yelena - an RN- they have devoted their professional lives to patients with heart disease from rare Neuroendocrine tumors. They have mentored 5 children, and are now learning from them and their 6 grandchildren have provided the real fuel and excitement for their lives. TOP TEN QUESTIONS ABOUT EXTERNAL RADIATION THERAPY: What is carcinoid heart disease (CHD) and what causes it to happen? Is CHD related to carcinoid symptoms? If my symptoms are uncontrolled, does this mean I might develop CHD? How concerned should I be about developing carcinoid heart disease? Which NET patients “get” CHD? Is it “inevitable”? Is it more common with NETs of the small bowel? Do those with NETs in the pancreas or other types of NETs ever get carcinoid heart disease? What are some of the signs and symptoms of carcinoid heart disease? How is it diagnosed? How does someone know if they have carcinoid heart disease? What is a heart murmur and how is it related to carcinoid heart disease? What is the appropriate testing for CHD? Are there blood tests that can or should be done? If someone is found to have neuroendocrine cancer (neuroendocrine tumor or NET) and CHD, what is the treatment approach? Which do you treat first and why? What is the treatment for CHD and how is this determined? If valve replacement is done, how many valves and which valves might be replaced? What type of valves are recommended? How is this done? What screening should be done for CHD and how often should someone get screened? How can I prevent CHD? What type of doctor(s) treat CHD? How do I know if I’m with a specialist? Bonus: What do you see as the future of CHD management and treatment? RESOURCES WATCH READ CHD Guidelines & Articles: ENETS guidance paper for carcinoid syndrome and carcinoid heart disease Davar et al (2017) Diagnosing and Managing Carcinoid Heart Disease in Patients With Neuroendocrine Tumors: An Expert Statement. J Am Coll Cardiol.; 69 (10) 1288–1304 Jin et al (2021) Carcinoid Heart Disease: Pathophysiology, Pathology, Clinical Manifestations, and Management. Cardiology;146:65–73 Ram et al (2019) Carcinoid Heart Disease:Review of Current Knowledge. Texas Heart Institute Journal February 2019, Vol. 46, No. 1 Additional Resources: Xermelo or Telotristat Ethyl Interscience Institute provides NET Diagnostic Testing including pancreastatin and serotonin. DISCLAIMER The Neuroendocrine Cancer Foundation Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of the Neuroendocrine Cancer Foundation. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS

<< Go back to the Podcast page EPISODE 42: NEUROENDOCRINE CANCER STRAIGHT TALK Download a Transcript of this Episode >>> ABOUT THIS EPISODE In this special episode, medical oncologist and NET expert, Dr. Diane Reidy-Lagunes engages in an open and honest discussion on sensitive topics including sexual health, family planning and end-of-life discussions. She also answers common questions regarding cannabis use with cancer as well as the relationship between sugar and cancer. Dr. Reidy shares information and insights from her decades of experience as well as from the award-winning “Cancer Straight Talk” podcast from Memorial Sloan Kettering Cancer Center (MSKCC) she created and hosted, and she relates these topics to NET patients and their loved ones. MEET DR. DIANE REIDY-LAGUNES Dr. Diane Reidy-Lagunes will join the Department of Medicine (DOM) as chief of the Division of Medical Oncology, effective April 1, 2025. In addition to her role with DOM, Dr. Reidy-Lagunes will also hold an appointment as Associate Vice President for Oncology Services for Duke University Health System. Dr. Reidy-Lagunes comes to Duke from Memorial Sloan Kettering Cancer Center (MSKCC), where she served as the vice chair of Medicine focused on coordination of care in MSKCC Regional Care Network. Her previous roles included president of MSKCC’s Medical Staff, associate deputy physician-in-chief for clinical operations in the Regional Care Network, physician liaison for the Patient and Family Advisory Council on Quality, clinical director for the GI oncology service, and co-director of the Medical Oncology/Hematology Fellowship Program in the Department of Medicine. During the COVID-19 crisis in New York City, she served as chief of clinical care as part of the Hospital Incident Command System at MSKCC. Additionally, she is the creator and host of an award-winning monthly podcast called "Cancer Straight Talk" from MSKCC which connects patients to cancer experts with the goal of having evidenced-based conversations on a variety of topics in cancer care. As a researcher, Dr. Reidy-Lagunes focuses on developing methods to integrate molecular-based therapies into the treatment of neuroendocrine and adrenal tumors. She is a member of the National Cancer Institute Task Force on Neuroendocrine Tumors and the National Cancer Care Network Guidelines, and she is a former board member of the North American Neuroendocrine Tumor Society. She has received numerous awards and honors, including the Paul Sherlock Resident Housestaff Teaching Award and recognition as one of Castle Connolly's Top Doctors. TOP TEN QUESTIONS ABOUT EXTERNAL RADIATION THERAPY: What is cancer? Is NET cancer? Should I follow a certain diet? Does sugar feed cancer? Can I exercise if I have metastatic neuroendocrine cancer? What does having neuroendocrine cancer mean for my romantic life? How does it affect dating? What does having neuroendocrine cancer mean for my sexual health? What does having neuroendocrine cancer mean for fertility and family planning? Can I have children? How do I talk to my kids about cancer? How will I know when it’s time for end-of-life discussions? Should I consider cannabis? What advice do you have about improving communication with my doctor? RESOURCES LISTEN MSK’s Cancer Straight Talk Podcast Series with Dr. Diane Reidy Episodes mentioned in this podcast: Episode 2 - Understanding the Basics of the “C-word”: What is Cancer with Dr. Matthew Matasar Episode 6 - Sugar and Cancer: Friend or Foe with Dr. Santosha Vardhana Episode 5 -Making Every Step Count: The Role of Exercise and Cancer Episode 34 - How Exercise Can Help Treat and Prevent Cancer with Dr. Lee Jones Episode 35 - Dating After a Cancer Diagnosis Episode 20 - A Man’s Guide to Sex and Cancer Episode 59 - Preserving Fertility During Cancer Treatment: Options, Costs and Success Rates Episode 56 - How to Talk to Children About Cancer Episode 23 - What’s the Hash on the Little Green Plan (Cannabis) and Cancer? MSK’s Death over Dinner The LACNETS Podcast Episode 37: Supportive Oncology for Neuroendocrine Cancer WATCH DISCLAIMER The Neuroendocrine Cancer Foundation Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of the Neuroendocrine Cancer Foundation. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS